
Editor's Note: At the 2026 ESMO Congress, Professor Barbara Pistilli of Gustave Roussy Cancer Center, France, presented updated results from VIKTORIA-1 Study 2 in patients with PIK3CA-mutant disease. The study showed that both the gedatolisib triplet combination (gedatolisib + palbociclib + fulvestrant) and the doublet combination (gedatolisib + fulvestrant) significantly improved progression-free survival (PFS) compared with alpelisib plus fulvestrant, regardless of whether patients had visceral or liver metastases. Based on these findings, Oncology Frontier interviewed Professor Barbara Pistilli at the congress to discuss the subgroup analyses, safety data, and clinical implications of the study.
Study Overview
Background
Gedatolisib (Geda) is a PI3K/mTOR inhibitor that blocks the PAM pathway. VIKTORIA-1 enrolled patients with HR-positive/HER2-negative advanced breast cancer (ABC) into two studies according to their PIK3CA mutation status: wild-type (WT) and mutant (MT). Both studies met their primary endpoint of median progression-free survival (mPFS) (Hurvitz et al., JCO 2026; ASCO 2026), supporting FDA approval for patients with PIK3CA wild-type advanced breast cancer. This article reports updated results from VIKTORIA-1 Study 2 in patients with PIK3CA-mutant disease, including subgroup efficacy outcomes and a more detailed safety analysis.
Methods
In VIKTORIA-1 Study 2, patients were randomized in a 3:3:1 ratio to one of three treatment arms:
- Gedatolisib + palbociclib + fulvestrant (geda + palbo + fulv; Arm D, n=155);
- Alpelisib + fulvestrant (alpelisib + fulv; Arm E, n=155); or
- Gedatolisib + fulvestrant (geda + fulv; Arm F, n=52).
All treatments were administered in 28-day cycles.
Results
VIKTORIA-1 Study 2 met its primary endpoint, with the gedatolisib + palbociclib + fulvestrant arm demonstrating a significant improvement in mPFS compared with the alpelisib + fulvestrant arm. This benefit was also observed in patients with visceral metastases (9.8 vs. 5.6 months; HR, 0.52; 95% CI, 0.37–0.74) and those without visceral metastases (21.5 vs. 9.2 months; HR, 0.38; 95% CI, 0.19–0.82), as well as in patients with liver metastases (9.1 vs. 4.6 months; HR, 0.47; 95% CI, 0.31–0.70) and those without liver metastases (21.5 vs. 9.1 months; HR, 0.46; 95% CI, 0.28–0.78).
Gedatolisib + fulvestrant also improved mPFS compared with alpelisib + fulvestrant in patients with visceral metastases (11.3 vs. 5.6 months; HR, 0.53; 95% CI, 0.33–0.85) and those without visceral metastases (not reached vs. 9.2 months; HR, 0.40; 95% CI, 0.13–1.31). In patients with liver metastases, mPFS was 11.1 versus 4.6 months (HR, 0.38; 95% CI, 0.20–0.69), while a numerical improvement was observed in those without liver metastases (11.5 vs. 9.1 months; HR, 0.71; 95% CI, 0.37–1.39).
The median duration of response (DOR), assessed according to RECIST v1.1 criteria and including unconfirmed partial responses (PRs), was longer in the gedatolisib-containing treatment arms: 19.4 months (95% CI, 11.1–25.1) with gedatolisib + palbociclib + fulvestrant; 27.8 months (95% CI, 9.2–NE) with gedatolisib + fulvestrant; and 7.5 months (95% CI, 5.6–16.6) with alpelisib + fulvestrant.
Treatment-emergent adverse events (TEAEs; ≥1%) leading to gedatolisib discontinuation occurred in eight patients (5.2%) in Arm D and two patients (3.8%) in Arm F. These included stomatitis (1.3% and 0%, respectively), infusion-related reactions (0% and 1.9%, respectively), and pneumonitis (0% and 1.9%, respectively). Most cases of stomatitis occurred within the first one to two weeks of treatment, and the incidence of Grade 3 stomatitis was below 3% after Cycle 2. Gedatolisib-containing regimens had no clinically meaningful effect on fasting or non-fasting blood glucose levels.
Conclusions
These results provide further support for gedatolisib-containing combination regimens in patients with HR-positive/HER2-negative, PIK3CA-mutant advanced breast cancer.
Expert Commentary
Oncology Frontier: I am a medical oncologist, and I have just presented the updated results of VIKTORIA-1 Study 2. This study evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, versus alpelisib plus fulvestrant in patients with PIK3CA-mutant, HR-positive/HER2-negative advanced breast cancer whose disease had progressed after treatment with a CDK4/6 inhibitor.
Gedatolisib is a potent pan-PI3K/mTORC1/2 inhibitor. Based on results in patients with PIK3CA wild-type (WT), HR-positive/HER2-negative advanced breast cancer who had received at least one line of endocrine therapy in the metastatic setting, gedatolisib in combination with fulvestrant, with or without palbociclib, has received FDA approval. In VIKTORIA-1 Study 2, both the gedatolisib + palbociclib + fulvestrant triplet and the gedatolisib + fulvestrant doublet significantly improved PFS compared with alpelisib + fulvestrant in patients with PIK3CA-mutant, HR-positive/HER2-negative advanced breast cancer.
Median PFS (mPFS) was 11.1 months in the triplet arm (HR, 0.50; 95% CI, 0.37–0.68; P<0.0001) and 11.3 months in the doublet arm (HR, 0.51; 95% CI, 0.33–0.79; P=0.0013).
At this year’s ESMO Congress, the results I presented focused primarily on additional efficacy subgroup analyses in patients with PIK3CA-mutant disease in VIKTORIA-1 Study 2, particularly PFS outcomes in patients with or without visceral or liver metastases, as well as a more detailed analysis of adverse events. These findings once again highlight the benefits of the gedatolisib triplet and doublet combinations over alpelisib plus fulvestrant, regardless of the presence or absence of visceral or liver metastases.
The results showed that patients in the triplet arm derived significant benefit regardless of liver metastasis status, while patients in the doublet arm also experienced a significant benefit if they had liver metastases. Among patients without liver metastases, median PFS was 21.5 months with the triplet, compared with 9.1 months with alpelisib (HR, 0.46). A similar trend was observed with the doublet (11.5 vs. 9.1 months; HR, 0.71).
In addition, we reported further safety findings. In particular, the discontinuation rate was lower in the gedatolisib arms than in the alpelisib arm: 5% with the triplet and 4% with the doublet, compared with 19% of patients in the alpelisib arm who discontinued treatment because of adverse events. Finally, we presented a more detailed analysis of the longitudinal pattern of stomatitis, the most common adverse event. Grade 3 stomatitis was rare and infrequent, and its duration was short, with most patients improving to a lower grade within one to two weeks.
We believe these findings further reinforce the potential of combination strategies as another valuable treatment option for patients with PIK3CA-mutant, HR-positive/HER2-negative advanced breast cancer.
Barbara Pistilli